These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32814850)

  • 1. Cancer surveillance for individuals with Li-Fraumeni syndrome.
    Kratz CP; Villani A; Nichols KE; Schiffman J; Malkin D
    Eur J Hum Genet; 2020 Nov; 28(11):1481-1482. PubMed ID: 32814850
    [No Abstract]   [Full Text] [Related]  

  • 2. Is Li-Fraumeni syndrome really much more common?
    Thomas DM
    Hum Mutat; 2017 Dec; 38(12):1619. PubMed ID: 29091331
    [No Abstract]   [Full Text] [Related]  

  • 3. Spectrum and Incidence of Skin Cancer among Individuals with Li-Fraumeni Syndrome.
    Hatton JN; Sargen MR; Frone MN; de Andrade KC; Savage SA; Khincha PP
    J Invest Dermatol; 2022 Sep; 142(9):2534-2537.e1. PubMed ID: 35183552
    [No Abstract]   [Full Text] [Related]  

  • 4. Pilot study of the prevalence of autoimmune disorders in Li-Fraumeni syndrome.
    Obregón IH; de Andrade KC; Bremer RC; Khincha PP; Savage SA
    Fam Cancer; 2023 Jul; 22(3):319-321. PubMed ID: 36627407
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
    Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
    J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and imaging surveillance in Li-Fraumeni syndrome.
    Raskind WH; Hisama FM; Bennett RL
    Lancet Oncol; 2016 Nov; 17(11):e472. PubMed ID: 27819239
    [No Abstract]   [Full Text] [Related]  

  • 7. Biochemical and imaging surveillance in Li-Fraumeni syndrome - Authors' reply.
    Villani A; Malkin D
    Lancet Oncol; 2016 Nov; 17(11):e473. PubMed ID: 27819240
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification of a novel TP53 germline mutation in a large Italian Li-Fraumeni syndrome Family.
    Capra V; Consales A; Nozza P; Monti P; Inga A; Fronza G
    Pediatr Blood Cancer; 2009 Feb; 52(2):303-4. PubMed ID: 18937320
    [No Abstract]   [Full Text] [Related]  

  • 9. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome.
    Barlow JW; Mous M; Wiley JC; Varley JM; Lozano G; Strong LC; Malkin D
    Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1403-6. PubMed ID: 15298965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.
    Bojadzieva J; Amini B; Day SF; Jackson TL; Thomas PS; Willis BJ; Throckmorton WR; Daw NC; Bevers TB; Strong LC
    Fam Cancer; 2018 Apr; 17(2):287-294. PubMed ID: 28988289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is It Time to Incorporate Liquid Biopsy into High-Risk Cancer Surveillance Protocols in Li-Fraumeni Syndrome?
    Latham A; MacFarland SP; Walsh MF; Maxwell KN; Stadler ZK
    Cancer Discov; 2024 Jan; 14(1):23-25. PubMed ID: 38213298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Willingness of individuals with Li-Fraumeni syndrome to participate in a cancer prevention trial: a survey study.
    Struewe FJ; Schott S; de Zwaan M; Kratz CP
    Fam Cancer; 2023 Oct; 22(4):495-497. PubMed ID: 37351819
    [No Abstract]   [Full Text] [Related]  

  • 13. Li-Fraumeni versus Pseudo-Li-Fraumeni Syndrome: Key Insights for Interpreting Next-Generation Sequencing Reports in Patients with Suspected Cancer Predisposition Syndromes.
    Sorscher S; Desnoyers R; Ouyang K; Ramkissoon S
    Oncologist; 2017 Sep; 22(9):1084-1085. PubMed ID: 28592622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance of Dutch Patients With Li-Fraumeni Syndrome: The LiFe-Guard Study.
    Ruijs MWG; Loo CE; van Buchem CAJM; Bleiker EMA; Sonke GS
    JAMA Oncol; 2017 Dec; 3(12):1733-1734. PubMed ID: 28772294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline TP53 mutations and Li-Fraumeni syndrome.
    Varley JM
    Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Li-Fraumeni syndrome--a molecular and clinical review.
    Varley JM; Evans DG; Birch JM
    Br J Cancer; 1997; 76(1):1-14. PubMed ID: 9218725
    [No Abstract]   [Full Text] [Related]  

  • 17. Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations.
    Xu J; Qian J; Hu Y; Wang J; Zhou X; Chen H; Fang JY
    Sci Rep; 2014 Feb; 4():4223. PubMed ID: 24573247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Li-Fraumeni syndrome: the genetics and treatment considerations for the sarcoma and associated neoplasms.
    Upton B; Chu Q; Li BD
    Surg Oncol Clin N Am; 2009 Jan; 18(1):145-56, ix. PubMed ID: 19056046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome.
    Bougeard G; Limacher JM; Martin C; Charbonnier F; Killian A; Delattre O; Longy M; Jonveaux P; Fricker JP; Stoppa-Lyonnet D; Flaman JM; Frébourg T
    J Med Genet; 2001 Apr; 38(4):253-7. PubMed ID: 11370630
    [No Abstract]   [Full Text] [Related]  

  • 20. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome.
    Kratz CP; Achatz MI; Brugières L; Frebourg T; Garber JE; Greer MC; Hansford JR; Janeway KA; Kohlmann WK; McGee R; Mullighan CG; Onel K; Pajtler KW; Pfister SM; Savage SA; Schiffman JD; Schneider KA; Strong LC; Evans DGR; Wasserman JD; Villani A; Malkin D
    Clin Cancer Res; 2017 Jun; 23(11):e38-e45. PubMed ID: 28572266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.